Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 2;21:588. doi: 10.1186/s12967-023-04468-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Functional annotation of the mtPCDI signature. A Association between known clinical and molecular features (age, gender, grade, chemotherapy status, radiotherapy status, IDH1 status, MGMT promoter methylation status, 1p/19q codeletion, TERT promoter methylation status, TERT expression status, and ATRT status) and mRNAsi in LGG. B Association between known clinical and molecular features (age, gender, grade, chemotherapy status, radiotherapy status, IDH1 status, MGMT promoter methylation status, 1p/19q codeletion, TERT promoter methylation status, TERT expression status, and ATRT status) and mDNAsi in LGG. C Correlation between mRNAsi and mtPCDI, and mRNAsi difference between two mtPCDI groups. D Correlation between mDNAsi and mtPCDI, and mDNAsi difference between two mtPCDI groups. E Correlation between TIS and mtPCDI, and TIS difference between high- and low-mtPCDI groups. F Box plot portrays the dissimilarities in cancer immunity cycle between two mtPCDI groups. G Radar plot displaying the tumor-infiltrating immunecells between two mtPCDI groups. H The bar plot shows the relative proportion of tumor-infiltrating immunecells. I Heatmap illustrates the expression levels of 178 step-specific signature genes associated with anti-cancer immunity across all samples in the seven-step Cancer-Immunity Cycle. *p < 0.05; **p < 0.01; ***p < 0.001; ns, no statistical significance